1. Disease summary:
Ulcerative colitis (UC) is a chronic, idiopathic inflammatory bowel disease characterized by continuous mucosal inflammation of the colon, starting from the rectum and extending proximally to varying extents. It presents with symptoms such as abdominal pain, bloody diarrhea, urgency, and weight loss. UC follows a relapsing-remitting course and affects approximately 5 million people worldwide, with significant morbidity including hospitalization and risk of colorectal cancer. The disease severity ranges from mild to severe, with acute severe ulcerative colitis (ASUC) representing a medical emergency requiring prompt intervention.
2. Standard of care:
The current standard of care for ulcerative colitis is a comprehensive, patient-centered approach aimed at inducing and maintaining remission, preventing complications, and improving quality of life. The management is stratified based on disease severity (mild, moderate, severe) and prior treatment exposure, with evolving therapeutic options.
Pharmacological Management:
- Mild to Moderate UC:
- First-line therapy typically involves 5-aminosalicylates (5-ASAs), including mesalamine in various formulations (oral and topical). These agents are effective for induction and maintenance of remission.
- Corticosteroids are used for induction in patients who do not respond adequately to 5-ASAs but are not recommended for maintenance due to side effects.
- Immunomodulators (e.g., thiopurines) may be considered for maintenance in steroid-dependent patients but are not recommended for induction monotherapy.
- Moderate to Severe UC:
- Advanced therapies include biologics and small molecules. The 2024 American Gastroenterological Association (AGA) living guideline recommends:
- Biologics: Anti-TNF agents (infliximab, adalimumab, golimumab), anti-integrin (vedolizumab), and anti-IL-12/23 agents (ustekinumab).
- Small molecules: Janus kinase (JAK) inhibitors (tofacitinib, upadacitinib), sphingosine-1-phosphate receptor modulators (ozanimod, etrasimod), and IL-23 inhibitors (risankizumab, guselkumab, mirikizumab).
- For biologic-naive patients, higher-efficacy agents such as infliximab, vedolizumab, ozanimod, upadacitinib, risankizumab, and guselkumab are preferred.
- For patients with prior biologic exposure, tofacitinib, upadacitinib, and ustekinumab are favored.
- Combination therapy of anti-TNF agents with immunomodulators is suggested over monotherapy to improve efficacy.
- Thiopurine monotherapy is not recommended for induction but may be used for maintenance in select cases.
- Methotrexate monotherapy is not recommended for induction or maintenance.
- Advanced therapies include biologics and small molecules. The 2024 American Gastroenterological Association (AGA) living guideline recommends:
- Acute Severe Ulcerative Colitis (ASUC):
- Requires hospitalization and intravenous corticosteroids as first-line therapy.
- Patients refractory to steroids may receive second-line therapies such as cyclosporine or infliximab.
- Surgical intervention (total colectomy with end ileostomy) is indicated for medically refractory cases or complications.
- Emerging therapies and personalized approaches are under investigation.
Treatment Goals:
- Achieving clinical remission (symptom resolution).
- Endoscopic remission (mucosal healing) is now considered the standard of care and a key therapeutic target.
- Histological remission and disease clearance (clinical, endoscopic, and histological remission) are emerging as important goals to improve long-term outcomes.
Monitoring and Surveillance:
- Non-invasive biomarkers such as fecal calprotectin and C-reactive protein are used for disease monitoring.
- Intestinal ultrasound and colon capsule endoscopy are emerging tools for non-invasive assessment.
- Surveillance colonoscopy with biopsies is recommended starting 8-10 years after diagnosis to detect dysplasia and prevent colorectal cancer, repeated every 1-2 years based on risk stratification.
Additional Considerations:
- Patient education, shared decision-making, and individualized treatment plans are emphasized.
- Nutritional support and management of extraintestinal manifestations are integral parts of care.
- Emerging therapies and microbiome-based treatments (e.g., fecal microbiota transplantation) are under investigation but not yet standard.
3. Additional context:
- The management landscape for UC is rapidly evolving with new biologics and small molecules expanding therapeutic options.
- Personalized medicine approaches, including multi-omics and predictive biomarkers, are anticipated to optimize treatment selection.
- The AGA living guideline model allows continuous updates as new evidence emerges.
- Surgical techniques for refractory disease have advanced, with minimally invasive and transanal approaches improving outcomes.
4. References:
- Singh S, Loftus EV Jr, Limketkai BN, et al. AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis. Gastroenterology. 2024 Dec. PMID: 39572132.
- Ananthakrishnan AN, Murad MH, Scott FI, et al. Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 AGA Evidence Synthesis. Gastroenterology. 2024 Dec. PMID: 39425738.
- Riviere P, Li Wai Suen C, Chaparro M. Acute severe ulcerative colitis management: unanswered questions and latest insights. Lancet Gastroenterol Hepatol. 2024 Mar. PMID: 38340753.
- D'Amico F, Magro F, Dignass A. Practical management of mild-to-moderate ulcerative colitis: an international expert consensus. Expert Rev Gastroenterol Hepatol. 2024 Aug. PMID: 39225555.
- Louis E, Schreiber S, Panaccione R. Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials. JAMA. 2024 Sep 17. PMID: 39037800.
- AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis
- Living guideline for moderate-to-severe ulcerative colitis - AGA
- ECCO Guidelines on Therapeutics in Ulcerative Colitis
If you need more detailed information on any specific aspect, please let me know!